High-throughput molecular profiling of high-grade astrocytomas: The utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH)

Journal of Neuropathology and Experimental Neurology

Volumn 61, Issue 12, 2002, Pages 1078-1084

  Fuller, Christine E ^a   Wang, Huamin ^b   Zhang, Wei ^c   Fuller, Gregory N ^c   Perry, Arie ^a,d  

^a BARNES JEWISH HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorescence in situ hybridization (FISH); Glioma; Microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CHROMOSOME 10; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME DELETION; CONTROLLED STUDY; DNA MICROARRAY; FEASIBILITY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MOLECULAR GENETICS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WORLD HEALTH ORGANIZATION;

EID: 0036898122     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/61.12.1078     Document Type: Article

References (44)

1. Perry A, Jenkins RB, O'Fallon J, et al. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. Cancer 1999;86:672-83
2. Kleihues P, Cavenee WK. World Health Organization classification of tumours. Pathology and Genetics of Tumours of the Central Nervous System. Lyon: IARC Press, 2000
3. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome lp loss. J Neurosurg 2000;92:983-90
4. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755-64
5. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: Occurrence, significance, and prognostic implications. Front Biosci 2000;5:213-31
6. Rey JA, Bello MJ, De Campos, et al. Chromosomal patterns in human malignant astrocytomas. Cancer Genet Cytogenet 1987;79: 201-21
7. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 1988;88:405-11
8. Jenkins RB, Kimmel DW, Meortel CA, et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet 1989;39:253-79
9. Bigner SH, Mark J, Bigner DD. Cytogenetics of human brain tumors. Cancer Genet Cytogenet 1990;47:141-54
10. Ransom DT, Ritland ST, Moertel CA, et al. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chrom Cancer 1992;5:357-74
11. Bello MJ, de Campos JM, Vaquero J, et al. Molecular and cytogenetic analysis of chromosome 9 deletions in 75 malignant gliomas. Genes Chrom Cancer 1994;9:33-41
12. Dalrymple SJ, Herath JE, Ritland SR, et al. Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas. J Neurosurg 1995;83:316-23
13. Amalfitano G, Chatel M, Paquis P, et al. Fluorescence in situ hybridization study of aneuploidy of chromosomes 7, 10, X, and Y in primary and secondary glioblastomas. Cancer Genet Cytogenet 2000;116:6-9
14. von Deimling A, Louis DN, von Ammon K, et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992:77:295-301
15. Hayashi Y, Ueki K, Waha A, et al. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871-75
16. Schmidt EE, Ichimura K, Goike HM, et al. Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts. J Neuropathol Exp Neurol 1999;58:1170-83
17. Zhou X-P, Li Y-J, Hoang-Xuan K, et al. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations. Int J Cancer 1999;83:150-54
18. Davies MP, Gibbs FEM, Halliwell N, et al. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer 1999;79:1542-48
19. Ueki K, Ono Y, Henson JW, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150-53
20. Ono Y, Tamiya T, Ichikawa T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996;55:1026-31
21. Perry A, Nobori T, Ru N, et al. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 1997;56:999-1008
22. Perry A, Anderl K, Borell TJ, et al. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas. Am J Clin Pathol 1999;112:801-9
23. von Deimling A, Louis DN, von Ammon K, et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992;52:4277-79
24. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on lp and 19q in human gliomas and their association with histologic subtype. Oncogene 1999;18:4144-52
25. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms lp and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18: 636-45
26. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 2002;12: 67-87
27. Bruch LA, Hill A, Cai DX, et al. A role for FISH detection of chromosome 22q dosage in distinguishing atypical teratoid/rhabdoid tumors from medulloblastoma/central primitive neuroectodermal tumor. Hum Pathol 2001;32:156-62
28. Cai DX, James CD, Scheithauer BW, Couch FJ, Perry A. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 2001;115:213-18
29. Cui J, Deubler DA, Rohr LR, et al. Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. Cancer Genet Cytogenet 1998;107:51-60
30. Arlt ME, Li M, Herzog TJ, Goodfellow PJ. A 1-Mb bacterial clone contig spanning the endometrial cancer deletion region of 1p32-p33. Genomics 1999;57:62-69
31. Kononen J, Bubendorf L, Kallioniemi ABM, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Med 1998;4:844-47
32. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-49
33. Moch H, Kononen J, Kallioniemi O-P, et al. Tissue microarrays: What will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001;8:14-20
34. Kallioniemi O-P, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62
35. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-22
36. Miettinen HE, Jarvinen TA, Kellner U, et al. High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 2000;26:504-12
37. Tynninen O, Paetau A, von Boguslawski K, et al. P53 expression in tissue microarray of primary and recurrent gliomas. Brain Pathol 2000;10:575-76
38. Wang H, Wang H, Zhang W, Fuller GN. Tissue microarrays: Applications in neuropathology research, diagnosis, and education. Brain Pathol 2002;12:95-107
39. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-6
40. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75
41. Caimcross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
42. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 2001; 158:1245-51
43. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: A new technology for amplification of tissue resources. Cancer J 2001;7: 24-31
44. Bubendorf L, Kononen J, Barlund M, et al. Tissue microarray FISH and digital imaging: Towards automated analysis of thousands of tumors with thousands of probes. Am J Hum Genet (Suppl) 1999;65:316